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Introduction
Shigellosis (i.e. bacillary dysentery) is a major public health burden 
in developing countries. Increased incidence of antibiotic resistance in 
Shigella flexneri (S. flexneri), constitute a major public health concern. 
S. flexneri is a non-motile, non-spore forming, non-lactose fermenting, 
Gram-negative, facultative anaerobic and rod shape bacterium, 
belongs to Enterobacteriaceae family. It mainly causes infection 
through contaminated food/water or with fecal matter [1,2]. Shigella 
spp. causes acute gastrointestinal infections by invasion to the mucosa 
(colonic epithelium), where it releases potent cytotoxin (shigatoxin) 
that causes severe local mucosal inflammation or ulceration due to low 
pH tolerant to acidic environment [3,4]. It does not produce gas from 
carbohydrates but ferment glucose predominately which is one of the 
characteristic features [5]. Manifestation of clinical complications in 
S. flexneri infected patients such as shigellosis (watery diarrhoea with 
mild vomiting), reactive arthritis and hemolytic uremic syndrome [6]. 
Shigellosis is predominantly a sexually transmitted disease, caused by 
Shigella spp. with direct oral-anal contact conferring the highest risk 
in HIV infected host [7]. Since, 2009 there has been an increase in 
UK-acquired infections amongst men who have sex with men (MSM). 
An outburst of S. flexneri amongst MSM has also described in North 
America in 2007 [8].
According to the United States Centers for Disease Control and 
Prevention (CDC)  reports, that more than one million deaths of the 
developing world occur per year due to infections with Shigella spp. 
[1]. From literature it has been also reported that Shigella species infect 
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Abstract
Shigellosis is a major public health burden in India and its neighboring countries due to infection of Shigella 
species. The current study was attempted to investigate the effect of biofield treatment on Shigella flexneri (S. 
flexneri) with respect of antimicrobial susceptibility assay, biochemical characteristics and biotyping. The American 
Type Culture Collection (ATCC 9199) strain of S. flexneri was used in this experiment. The study was conducted in 
revived and lyophilized state of S. flexneri. Both revived (Group; Gr. II) and lyophilized (Gr. III) strain of S. flexneri 
were subjected to Mr. Trivedi’s biofield treatment. Gr. II was assessed on day 5 and day 10, while Gr. III on day 
10 after biofield treatment with respect to control (Gr. I). The antimicrobial susceptibility of S. flexneri showed 35% 
alteration in Gr. II on day 10 while no alteration were observed on day 5 (Gr. II) and in Gr. III as compared to control. 
The minimum inhibitory concentration (MIC) values of biofield treated S. flexneri also showed significant (46.88%) 
alteration in Gr. II on day 10 while no alteration were observed on day 5 (Gr. II) and in Gr. III as compared to control. 
It was observed that overall 24.24% biochemical reactions were altered in which 21.21% alteration was found in Gr. 
II on day 10 with respect to control. Moreover, biotype number was changed in Gr. II on day 10 with identification of 
new organism i.e. Edwardsiella tarda (40015042) as compared to untreated strain of Shigella species (40010000). 
The result suggested that biofield treatment has significant impact on S. flexneri in revived treated cells (Gr. II) on day 
10 with respect to antimicrobial susceptibility, MIC, biochemical reactions pattern and biotyping. 
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∼450,000 persons annually in the United States [7], resulting in 6200
hospitalizations and 70 deaths [9]. National Institute of Cholera and 
Enteric Diseases (NICED) reported that high frequency of resistance in 
Shigella against many of the first line antimicrobial agents (multidrug 
resistant) have been reported in recent years [10]. Fluoroquinolone 
or ceftriaxone are the drug of choice to treat shigellosis. However, 
due to high tendency of multidrug resistance globally including 
fluoroquinolones and newer cephalosporins, particularly in South and 
East Asia [11], some alternative strategies are needed to treat against 
strain of S. flexneri. 
Harold Saxton Burr, had performed the detailed studies on 
correlation of electric current with physiological process and concluded 
that every single process in the human body had an electrical significance 
[12]. Furthermore, the energy exists in various forms and there are 
several ways to transfer the energy from one place to another such as 
electromagnetic waves, electrochemical, electrical and thermal etc. 
Similarly, the human nervous system consists of neurons, which have 
the ability to transmit information and energy in the form of electrical 
signals [13]. According to Rivera-Ruiz et al. electrocardiography has 
been extensively used to measure the biofield of human body [14]. 
Thus, human has the ability to harness the energy from environment or 
Universe and can transmit into any living or nonliving object(s) around 
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the Globe. The objects always receive the energy and responding into 
useful way that is called biofield energy and the process is known as 
biofield treatment. Mr. Trivedi’s unique biofield treatment (The Trivedi 
Effect®) has been known to transform the structural, physical and 
thermal properties of several metals and ceramic in materials science 
[15-17], improved the overall productivity of crops [18,19], altered 
characteristics features of microbes [20-22] and improved growth and 
anatomical characteristics of various medicinal plants [23,24].
Due to the clinical significance of this organism and literature 
reports on biofield treatment as an alternative approach, the present 
work was undertaken to evaluate the impact of biofield treatment on S. 
flexneri in relation to antimicrobials susceptibility, minimum inhibitory 
concentration (MIC) and biotyping based on various biochemical 
characters.
Materials and Methods
S. flexneri, American Type Culture Collection (ATCC 9199) strains 
were procured from MicroBioLogics, Inc., USA, in two sets A and B. 
Two different sealed packs were stored with proper storage conditions 
until further use. The antimicrobial susceptibility, MIC values, 
biochemical reactions and biotype number were estimated with the 
help of MicroScan Walk-Away® (Dade Behring Inc., West Sacramento, 
CA, USA) using negative breakpoint combo 30 (NBPC 30) panel. All 
the tested antimicrobials and biochemicals were procured from Sigma-
Aldrich (MA, USA).
Experimental design
Two ATCC samples A (revived) and B (lyophilized) of S. flexneri 
were grouped (Gr.). The revived sample A was divided into two parts 
Gr.I (control) and Gr.II (revived; treatment); likewise, ATCC B was 
labeled as Gr.III (lyophilized; treatment). 
Biofield treatment strategy
The Gr. I remained as untreated. The treatment Gr. II and III in sealed 
packs were handed over to Mr. Trivedi for biofield treatment under 
laboratory condition. Mr. Trivedi provided the treatment through his 
energy transmission process which includes bioenergy emission to the 
treated groups (Gr. II and Gr. III) without touching the samples. After 
treatment, sample was handed over in the same condition and stored 
at standard conditions as per the standard experimental protocol. An 
optimum precautionary measure were taken while evaluating the study 
parameters throughout the experiments. The differences in parameters 
before and after the treatment were noted and compared. Gr.II was 
assessed at two time point i.e. on day 5 and day 10, while Gr. III was 
assessed on day 10 for antimicrobial susceptibility, MIC, biochemical 
reactions pattern, and biotyping.
Antimicrobial susceptibility test
Investigation of antimicrobial susceptibility of S. flexneri was 
carried out with the help of automated instrument, MicroScan Walk-
Away® using NBPC 30 panel as per the clinical and laboratory standards 
institute (CLSI) guidelines. The test was carried out on MicroScan 
which was miniaturized of the broth dilution susceptibility test that 
has been dehydrated. Briefly, the standardized suspension of S. flexneri 
was inoculated, rehydrated, and then subjected to incubation for 16 
hours at 35°C. The detailed experimental procedures and conditions 
were followed as per the manufacturer’s instructions. The antimicrobial 
susceptibility pattern (S: Susceptible, R: Resistant; and I: Intermediate) 
and MIC were determined by observing the lowest antimicrobial 
concentration showing inhibition of growth [25].
Biochemical reaction studies
Biochemical reactions of S. flexneri were determined using 
MicroScan Walk-Away®, system with NBPC 30 panel [25].
dentification of organism by biotype number 
The biotype number of S. flexneri was determined on MicroScan 
Walk-Away® processed panel data report with the help of biochemical 
reactions data [25].
Results and Discussion
Antimicrobial susceptibility test 
The outcomes of S. flexneri susceptibility pattern and MIC values 
of tested antimicrobials after biofield treatment are summarized in 
Tables 1 and 2, respectively. The data were analyzed and compared 
with respect to the control. Antimicrobial susceptibility was carried 
out in twenty antimicrobials. The revived treated cells (Gr. II) of S. 
flexneri showed a significant alteration in antimicrobial sensitivity 
pattern i.e. 35% (seven out of twenty) on day 10, while did not 
show any alteration of antimicrobial sensitivity pattern on day 5 
(Gr. II) and in Gr. III as compared to the control. Antimicrobials 
such as amoxicillin/k-clavulanate, ampicillin/sulbactam, ampicillin, 
aztreonam, chloramphenicol, and trimethoprim/sulfamethoxazole 
showed an alteration of susceptibility pattern from S to R in Gr. II on 
day 10 as compared to the control. Alteration of resistance pattern of 
these antimicrobials may be due to the changes at genetic level that 
could be govern due to biofield energy treatment on S. flexneri [26]. 
According to routine antibiogram studies the resistance responses of 
chloramphenicol and trimethoprim/sulfamethoxazole and susceptible 
responses of ciprofloxacillin and imipenem were well supported by 
literature data [27]. However, these antimicrobials did not show any 
change on day 5 in Gr. II and on day 10 in Gr. III as compared to the 
control. Antibiotic i.e. ceftazidime showed an alteration of sensitivity 
pattern from susceptible to intermediate in Gr. II on day 10, while 
remain unchanged on day 5 (Gr. II) and in Gr. III on day 10 as compared 
to control. Rest of antimicrobials i.e. 65% out of twenty viz. cefepime, 
cefotaxime, ceftriaxone, ciprofloxacin, gatifloxacin, imipenem, 
levofloxacin, meropenem, moxifloxacin, piperacillin/tazobactam, 
piperacillin, tetracycline, and ticarcillin/k-clavulanate did not show any 
change of antimicrobial sensitivity after biofield treatment with respect 
to control sample (Table 1). The sensitivity patterns of both cefotaxime 
and ceftriaxone in control S. flexneri sample were matched with 
literature data [28]. The MIC values of amoxicillin/k-clavulanate and 
ampicillin/sulbactam were increased from ≤8/4 to >16/8 µg/mL (i.e. 
two-fold increase) in Gr. II on day 10 while remain unchanged on day 
5 (Gr. II) and in Gr. III on day 10 as compared to control. Alteration of 
MIC values of ampicillin, aztreonam, cefazolin, cefoxitin, cephalothin 
and chloramphenicol were altered from ≤8 to >16 µg/mL (i.e. two-fold) 
in Gr. II on day 10 while remain unchanged on day 5 in Gr. II and on 
day 10 in Gr. III as compared to control. Moreover, change in MIC value 
of cefotetan from ≤16 to >32 µg/mL (i.e. two-fold) was observed in Gr. 
II on day 10 after biofield treatment, while did not change on day 5 in 
Gr. II and on day 10 in Gr. III as compared to control. The MIC value of 
ceftazidime was changed from ≤8 to 16 µg/mL (i.e. two-fold) on day 10 
in Gr. II, while remain unaltered on day 5 in Gr. II and on day 10 in Gr. 
III as compared to control. The MIC value of cefuroxime was changed 
from ≤4 to >16 in Gr. II on day 10 as compared to control. The MIC 
values of extended spectrum β-lactamases (ESBL) a Scrn and b Scrn 
were changed from ≤4 to >4 and ≤1 to >1 respectively in Gr. II on day 
10 while no change of MIC values were observed in Gr. II (on day 5) 
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and Gr. III as compared to control. Antimicrobials i.e. nitrofurantoin 
and trimethoprim/sulfamethoxazole showed an alteration of MIC 
values from ≤32 to >64 µg/mL (i.e. two-fold) and ≤2/38 to >2/38 µg/
mL respectively in Gr. II on day 10 while remain unchanged on day 5 
(Gr. II) and in Gr. III as compared to control. Overall, 46.88% (fifteen 
out of thirty two) antimicrobials showed altered MIC values after 
biofield treatment in Gr. II on day 10 while MIC values were remained 
unchanged on day 5 in Gr. II and on day 10 in Gr. III as compared to 
control. Seventeen, out of thirty two (53.13%) tested antimicrobials viz. 
amikacin, cefepime, cefotaxime, ceftriaxone, ciprofloxacin, gatifloxacin, 
gentamicin, imipenem, levofloxacin, meropenem, moxifloxacin, 
norfloxacin, piperacillin/tazobactam, piperacillin, tetracycline, 
ticarcillin/k-clavulanate and tobramycin did not show any alteration in 
MIC value in treated cells of S. flexneri as compared to control (Table 2). 
Biochemical reactions studies
Study of biochemical reactions can be utilized to identify 
the enzymatic and metabolic characteristic features of microbes. 
Microorganisms can be categorically differentiated based on their 
utilization of specific biochemicals as nutrients during the process 
of metabolism and/or enzymatic reactions. The specific biochemical, 
which showed some changes against S. flexneri after biofield treatment 
are shown in Table 3. Biochemicals such as cetrimide (CET), 
cephalothin (CF8), citrate (CIT), nitrofurantoin (FD64), kanamycin 
(K4), lysine (LYS) and ornithine (ORN) were changed from negative 
(-) to positive (+) reaction in Gr. II on day 10 while remain unaltered 
i.e. negative (-) reaction on day 5 in Gr. II and on day 10 in Gr. III with 
respect to control. Moreover, indole (IND) was changed from positive 
(+) to negative (-) reaction in Gr. III while remained unchanged i.e. 
positive (+) reaction in Gr. II on both day 5 as well as day 10 with 
respective to control. Overall, 24.24% (eight out of thirty three) 




Gr. II Gr. III
Day 5 Day 10 Day 10
1 Amoxicillin/k-clavulanate S S R S
2 Ampicillin/sulbactam S S R S
3 Ampicillin S S R S
4 Aztreonam S S R S
5 Cefepime S S S S
6 Cefotaxime S S S S
7 Ceftazidime S S I S
8 Ceftriaxone S S S S
9 Chloramphenicol S S R S
10 Ciprofloxacin S S S S
11 Gatifloxacin S S S S
12 Imipenem S S S S
13 Levofloxacin S S S S
14 Meropenem S S S S
15 Moxifloxacin S S S S
16 Piperacillin/tazobactam S S S S
17 Piperacillin S S S S
18 Tetracycline S S S S
19 Ticarcillin/k-clavulanate S S S S
20 Trimethoprim/sulfamethoxazole S S R S
R: Resistant; I: Intermediate; S: Susceptible; Gr.: Group




Gr. I Gr. II Gr. III
Day 5 Day 10 (Day 10)
1 Amikacin ≤16 ≤16 ≤16 ≤16
2 Amoxicillin/k-clavulanate ≤8/4 ≤8/4 >16/8 ≤8/4
3 Ampicillin/sulbactam ≤8/4 ≤8/4 >16/8 ≤8/4
4 Ampicillin ≤8 ≤8 >16 ≤8
5 Aztreonam ≤8 ≤8 >16 ≤8
6 Cefazolin ≤8 ≤8 >16 ≤8
7 Cefepime ≤8 ≤8 ≤8 ≤8
8 Cefotaxime ≤8 ≤8 ≤8 ≤8
9 Cefotetan ≤16 ≤16 >32 ≤16
10 Cefoxitin ≤8 ≤8 >16 ≤8
11 Ceftazidime ≤8 ≤8 16 ≤8
12 Ceftriaxone ≤8 ≤8 ≤8 ≤8
13 Cefuroxime ≤4 ≤4 >16 ≤4
14 Cephalothin ≤8 ≤8 >16 ≤8
15 Chloramphenicol ≤8 ≤8 >16 ≤8
16 Ciprofloxacin ≤1 ≤1 ≤1 ≤1
17 ESBL-a Scrn ≤4 ≤4 >4 ≤4
18 ESBL-b Scrn ≤1 ≤1 >1 ≤1
19 Gatifloxacin ≤2 ≤2 ≤2 ≤2
20 Gentamicin ≤4 ≤4 ≤4 ≤4
21 Imipenem ≤4 ≤4 ≤4 ≤4
22 Levofloxacin ≤2 ≤2 ≤2 ≤2
23 Meropenem ≤4 ≤4 ≤4 ≤4
24 Moxifloxacin ≤2 ≤2 ≤2 ≤2
25 Nitrofurantoin ≤32 ≤32 >64 ≤32
26 Norfloxacin ≤4 ≤4 ≤4 ≤4
27 Piperacillin/tazobactam ≤16 ≤16 ≤16 ≤16
28 Piperacillin ≤16 ≤16 ≤16 ≤16
29 Tetracycline ≤4 ≤4 ≤4 ≤4
30 Ticarcillin/k-clavulanate ≤16 ≤16 ≤16 ≤16
31 Tobramycin ≤4 ≤4 ≤4 ≤4
32 Trimethoprim/sulfamethoxazole ≤2/38 ≤2/38 >2/38 ≤2/38
MIC data are presented in µg/mL; Gr.: Group; ESBL-a, b Scrn: Extended-
spectrum β-        lactamase screen a and b
Table 2: Effect of biofield treatment on Shigella flexneri to minimum inhibitory 
concentration (MIC) of tested antimicrobials.
to control after biofield treatment. Revived treated cells of S. flexneri 
(Gr. II) showed 21.21% and lyophilized treated cells (Gr. III) showed 
3.03% alteration on day 10 while no alteration was observed on day 5 in 
Gr. II in term of biochemical reactions as compared to control. About 
75.76% (out of thirty three) tested biochemicals, such as acetamide 
(ACE), adonitol (ADO), arabinose (ARA), arginine (ARG), colistin 
(CL4), esculin hydrolysis (ESC), glucose (GLU), hydrogen sulfide 
(H2S), inositol (INO), malonate (MAL), melibiose (MEL), nitrate 
(NIT), oxidation-fermentation/glucose (OF/G), ortho-nitrophenyl-β-
galactoside (ONPG), oxidase (OXI), penicillin (P4), raffinose (RAF), 
rhamnose (RHA), sorbitol (SOR), sucrose (SUC), tartrate (TAR), 
tryptophan deaminase (TDA), tobramycin (TO4), urea (URE) and 
Voges-Proskauer (VP) did not show any change in all the treated groups 
after biofield treatment as compared to control (Table 3).
Based on existing literature differentiation of specific Shigella 
serotype on the basis of their sugar fermentation pattern is difficult. 
The key characteristic feature for S. flexneri bacterium is non-lactose 
fermenting, but it can ferment glucose with production of acid [2]. 
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In this experiment, control sample of S. flexneri resulted positive 
(+) reaction in GLU and negative reaction (-) in case of SUC. The 
findings were also reported in the literature [29]. These findings could 
be due to fermentation of GLU and produce acid, which supports 
the characteristic feature of S. flexneri. In the present study, negative 
reactions (-) of VP and URE utilization tests were observed in control 
sample of S. flexneri. The findings were also reported in the literature 
[30]. 
Identification of Organism by Biotype Number 
The species (S. flexneri) was identified based on variety of 
conventional biochemical characters and biotyping. Biotype number 
of particular organism was evaluated after interpreting the results 
of the biochemical reactions. The biotype number then led to the 
particular organism identification. Based on the biochemical results, 
biotype number was changed in revived treated cells (Gr. II) on day 
10 (40015042) as compared to untreated strain of Shigella species 
(40010000). In Gr. II due to change in biotype number a new organism 
S. No. Code Biochemical
Type of Response
Gr. I Gr. II Gr. III
Day 5 Day 10 Day10
1 ACE Acetamide - - - -
2 ADO Adonitol - - - -
3 ARA Arabinose - - - -
4 ARG Arginine - - - -
5 CET Cetrimide - - + -
6 CF8 Cephalothin - - + -
7 CIT Citrate - - + -
8 CL4 Colistin - - - -
9 ESC Esculin hydrolysis - - - -
10 FD64 Nitrofurantoin - - + -
11 GLU Glucose + + + +
12 H2S Hydrogen sulfide - - - -
13 IND Indole + + + -
14 INO Inositol - - - -
15 K4 Kanamycin - - + -
16 LYS Lysine - - + -
17 MAL Malonate - - - -
18 MEL Melibiose - - - -
19 NIT Nitrate + + + +
20 OF/G Oxidation-fermentation/glucose + + + +
21 ONPG Galactosidase - - - -
22 ORN Ornithine - - + -
23 OXI Oxidase - - - -
24 P4 Penicillin + + + +
25 RAF Raffinose - - - -
26 RHA Rhamnose - - - -
27 SOR Sorbitol - - - -
28 SUC Sucrose - - - -
29 TAR Tartrate - - - -
30 TDA Tryptophan deaminase - - - -
31 TO4 Tobramycin - - - -
32 URE Urea - - - -
33 VP Voges-Proskauer - - - -
 ‘-’ (Negative); ‘+’ (Positive); Gr.: Group; ONPG: Ortho-nitrophenyl-β-galactoside
Table 3: Effect of biofield treatment on Shigella flexneri to the biochemical reaction 
pattern.
Feature Gr. I 
Gr. II Gr. III
Day 5 Day 10  Day 10












Table 4: Effect of biofield treatment on biotype number of Shigella flexneri.
i.e. Edwardsiella tarda was identified, which could be due to change in 
enzymatic and/or genetic level after biofield treatment. However, the 
biotype numbers of S. flexneri were not altered in Gr. II (on day 5) and 
Gr. III (on day 10) as compared to control (Table 4). 
Rapid emergence and outbreaks of resistant microorganisms due to 
widespread selective pressure and efficient dissemination channels are 
one of the factors that might have contributed to the spread of resistant 
organisms [31]. Due to microbial resistance to a single or multiple drugs, 
invention of an effective antimicrobial therapy for the human-wellness 
is urgently required. However, due to some limitation of science, the 
progress of new medications are slow and very challenging for scientists. 
Biofield treatment could be responsible for alteration in microorganism 
at genetic and/or enzymatic level, which may act on receptor protein. 
While altering receptor protein, ligand-receptor/protein interactions 
may alter that could lead to show different phenotypic characteristics 
[32]. Moreover, the alteration in susceptibility patterns may be due to 
mutation occurs at genetic level on biofield energy treated S. flexneri 
[33]. Biofield treatment might induce significant changes in revived 
strain of S. flexneri and alter antimicrobials susceptibility pattern, MIC 
values and biochemical reactions. Based on these results, it is postulated 
that, biofield treatment could be used to alter the sensitivity pattern of 
antimicrobials.  
Conclusions
Altogether, the biofield treatment has significantly altered the 
susceptibility pattern (35%) and MIC values (46.88%) of tested 
antimicrobials against the ATCC strain of S. flexneri in revived 
treated cells (Gr. II) on day 10 as compared to control. It also altered 
the biochemical reactions pattern (21.21%) in biofield treated 
strain of S. flexneri in Gr. II as compared to control. On the basis of 
changed biochemical reactions of S. flexneri the biotype number was 
altered in Gr. II with identification of new organism, Edwardsiella 
tarda (40015042) as compared to untreated strain of Shigella species 
(40010000). Mr. Trivedi’s biofield treatment could be applied as an 
alternative therapeutic approach to alter the sensitivity pattern of 
antimicrobials in near future. These findings suggest that there is a need 
to carry out extensive susceptibility studies at molecular level.
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